Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | -1.24% | 63.15 | 1.0% | $510.50m | |
| AMGN | Amgen, Inc. | -4.02% | 225.59 | 1.3% | $451.51m | |
| BIIB | Biogen, Inc. | -2.14% | 278.14 | 1.4% | $375.15m | |
| ILMN | Illumina, Inc. | -2.27% | 319.58 | 3.5% | $322.74m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -2.07% | 229.06 | 1.9% | $273.01m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -3.17% | 345.28 | 2.6% | $238.76m | |
| EXAS | EXACT Sciences Corp. | -2.83% | 89.57 | 24.0% | $223.37m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -3.02% | 105.27 | 2.0% | $170.84m | |
| A | Agilent Technologies, Inc. | -0.92% | 88.25 | 1.6% | $130.79m | |
| INCY | Incyte Corp. | -1.92% | 76.74 | 2.5% | $127.16m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 0.61% | 86.15 | 4.3% | $108.27m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.14% | 112.39 | 14.6% | $108.00m | |
| SGEN | Seattle Genetics, Inc. | -1.54% | 113.57 | 6.1% | $103.89m | |
| BLUE | bluebird bio, Inc. | -2.74% | 87.26 | 14.2% | $86.40m | |
| DERM | Dermira, Inc. | -0.27% | 18.71 | 3.8% | $83.32m |
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.